SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 4.4% Passive Stake in Haemonetics Corp/Mass

T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, reporting a 4.4% beneficial ownership stake in Haemonetics Corp/Mass as of March 31, 2025.

Summary

• T. Rowe Price Investment Management, Inc. (TRPIM) has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Haemonetics Corp/Mass.
• As of March 31, 2025, TRPIM beneficially owns 2,195,569 shares of Haemonetics Corp/Mass common stock.
• This ownership represents 4.4% of the total outstanding common stock of Haemonetics Corp/Mass.
• TRPIM holds sole voting power and sole dispositive power over all 2,195,569 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing disclosing a passive institutional ownership stake. While not directly positive or negative about the company's performance, the presence of a significant stake from a major investment firm like T. Rowe Price can be seen as a neutral to slightly positive indicator of institutional confidence.

Positives

• The disclosure of a significant stake by a reputable institutional investor like T. Rowe Price Investment Management can be viewed as a vote of confidence in Haemonetics Corp/Mass's long-term prospects.
• The passive nature of the investment, as certified by T. Rowe Price, indicates that the firm is not seeking to influence or change the control of Haemonetics, suggesting a stable institutional holding.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Haemonetics Corp/Mass's future performance or T. Rowe Price Investment Management's future investment intentions beyond the passive holding statement.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
• "T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."

Industry Context

This filing is a routine disclosure of institutional ownership, common in the financial industry where large asset managers like T. Rowe Price hold stakes in publicly traded companies. Haemonetics Corp/Mass operates in the medical technology sector, and such institutional investments are typical for established companies in this space.

Stakeholder Impact

• Shareholders: The disclosure of a significant, passive stake by a major institutional investor like T. Rowe Price may provide a degree of stability and confidence in the company's stock, as it indicates a long-term, non-activist investment.

Key Dates

Keywords

Haemonetics Corp/Mass, T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management